Clearstead Advisors’s Spyre Therapeutics SYRE Stock Holding History

Clearstead Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.27K	Buy	+48	New	+$4.62K	﹤0.01%	2254

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Clearstead Advisors's SYRE Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 48 shares worth $4.27K. The stake represents ﹤0.01% of the portfolio and ranks #2254 among its holdings.

114 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

Clearstead Advisors held 48 shares of Spyre Therapeutics worth $4.27K as of Q3 2026.
Spyre Therapeutics was a new Clearstead Advisors position in Q3 2026.
Spyre Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2254 holding.
114 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.